FDA Vaccine Chief Vinay Prasad to Leave Agency Again After Turbulent Tenure Marked by Drug and Vaccine Disputes

BY Rosemary

The U.S. Food and Drug Administration’s top vaccine and biotechnology regulator, Dr. Vinay Prasad, will once again depart the agency after a turbulent period marked by public disputes with pharmaceutical companies, policy reversals and mounting criticism from industry leaders and lawmakers.

FDA Commissioner Marty Makary informed agency staff in a late Friday email that Prasad will leave his position at the end of April. According to Makary, Prasad plans to return to his academic role at the University of California, San Francisco, where he previously worked as a professor and researcher before joining federal regulators.

The departure marks the second time in less than a year that Prasad has exited the agency following a series of controversies surrounding the FDA’s handling of vaccines, gene therapies and experimental treatments for rare diseases. His time in the position drew intense scrutiny from drug manufacturers, patient advocacy groups and political allies of President Donald Trump, who have sharply criticized several of the agency’s regulatory decisions.

Prasad first faced pressure last summer when he was briefly pushed out of his role after disagreements with biotechnology executives and patient organizations escalated into a broader political dispute. His removal lasted less than two weeks before he was reinstated with the backing of Health and Human Services Secretary Robert F. Kennedy Jr. and Commissioner Makary.

Since returning, however, tensions surrounding the agency’s regulatory decisions have only intensified. Critics within the pharmaceutical industry have accused the FDA of sending mixed signals to drug developers, particularly when it comes to therapies that had previously appeared to meet regulatory standards.

The latest controversy erupted over a highly anticipated influenza vaccine developed by Moderna using messenger RNA technology. The company had submitted an application seeking regulatory review of the vaccine, hoping it could represent the next step in the expansion of mRNA-based immunizations following the widespread use of COVID-19 shots.

In a highly unusual move, the FDA initially declined to review Moderna’s application, a decision that surprised industry observers and prompted the company to publicly challenge the agency’s position. Moderna executives made their objections known and indicated they would formally contest the rejection.

Within days of the dispute becoming public, the FDA reversed its stance. Agency officials said the vaccine would ultimately be accepted for review, though they required the company to conduct an additional study before the evaluation could proceed. The sudden shift raised questions among investors and pharmaceutical analysts about consistency in the agency’s decision-making process.

The controversy over the influenza vaccine was followed by another unusual confrontation between the FDA and a biotechnology company developing an experimental treatment for Huntington’s disease, a fatal genetic disorder that affects roughly 40,000 people in the United States.

UniQure, the company behind the gene therapy, said regulators demanded a new clinical trial that would include a so-called sham surgery for certain patients participating in the study. The therapy involves delivering genetic material directly into the brain through a surgical procedure, raising complex ethical questions about how placebo-controlled trials should be conducted.

Company executives argued that the FDA’s request contradicted earlier guidance and placed patients at unnecessary risk. They also warned that the requirement would significantly delay development of a treatment for a disease that currently has no cure.

In response, the FDA took the unusual step of publicly defending its position during a press conference with reporters. A senior agency official, speaking on condition of anonymity, strongly criticized the company’s original clinical trial and argued the data did not support the therapy’s effectiveness.

The official described the study’s results as unequivocally negative and suggested the product had failed to demonstrate meaningful benefit for patients. Such blunt public criticism of an experimental therapy is rare for the agency, which typically communicates disagreements with drug developers through carefully reviewed written statements rather than public briefings.

The exchange underscored the increasingly tense relationship between regulators and biotechnology firms during Prasad’s tenure. Several companies developing treatments for rare or hard-to-treat conditions have received rejection letters or demands for additional clinical trials, requirements that can delay approvals by years and add tens or even hundreds of millions of dollars to development costs.

Industry leaders say the additional studies have forced companies to rethink their strategies and, in some cases, scale back investment in certain therapies. Patient advocacy groups have also raised concerns that the heightened scrutiny could slow the arrival of treatments for people suffering from severe or life-threatening diseases.

Prasad, a longtime academic physician and prominent critic of the FDA’s traditional drug approval standards, had built a reputation for challenging the pharmaceutical industry’s clinical evidence before joining the agency. His appointment last year was seen by some observers as a signal that regulators might take a more skeptical approach to certain experimental drugs and vaccines.

At the same time, Prasad and Commissioner Makary repeatedly announced initiatives aimed at accelerating the FDA’s drug review process and reducing regulatory delays for companies. Those efforts were designed to speed the arrival of new medicines to market while also addressing criticism that the agency moves too slowly when evaluating treatments.

However, critics say the push for faster reviews has often clashed with stricter requirements imposed on some biotechnology products. Vaccines and gene therapies in particular have faced new study demands and safety warnings, a development that has fueled debate within the pharmaceutical sector.

The issue has been especially sensitive when it comes to COVID-19 vaccines and related technologies, which have long been a focus of criticism from Kennedy. Before joining the Trump administration as health secretary, Kennedy had been one of the most prominent figures in the anti-vaccine movement, frequently questioning the safety and effectiveness of immunizations.

As Prasad prepares to leave the FDA once again, the agency faces continued scrutiny over how it balances the need for rigorous scientific evidence with pressure to accelerate access to new medical treatments. His departure leaves unanswered questions about whether regulators will maintain the same approach toward drug approvals or adopt a different strategy under new leadership.

For now, Prasad is expected to return to academic medicine in California, ending a brief but contentious chapter at one of the world’s most influential drug regulatory agencies.